Briefing
MERMAID-2: durvalumab versus placebo for MRD-positive stage II to III NSCLC after curative therapy
Phase 3 trial of adjuvant durvalumab versus placebo in patients with resected stage II to III non-small cell lung cancer who become MRD-positive during surveillance without RECIST recurrence. ClinicalTrials.gov lists the study as completed.
- Design: Phase 3 · Completed